MONROVIA, Calif.--(BUSINESS WIRE)--July 11, 2006--Xencor, a biotherapeutics company developing protein and antibody therapeutics, today announced that it raised $6 million in a bridge financing from new investor Novo Nordisk and existing investors including Zen Investments. Pursuant to the bridge financing, Novo Nordisk has committed to invest an additional $6 million in specified future financings.
